Of note, regarding HER2-positive and TN breast cancer patients, an update on current ASCO guidelines endorsed a modulation in the adjuvant therapy even in the presence of residual tumor with unchanged intrinsic subtype [35]. This evidence concerns the gene ERBB2 and neoplasm.